Physician profile
Kurt Ashack
NPI 1073976338
$198,913.23
in general payments reported to CMS, 2019-2025
32 companies · $58K in 2025
The $58K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $345 · 2021: $1,601 · 2022: $20K · 2023: $40K · 2024: $79K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Consulting Fee: $17K · Food and Beverage: $7,087 · Travel and Lodging: $6,457 · Education: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $144,599.50 |
| Consulting Fee | $17,298.00 |
| Food and Beverage | $7,086.75 |
| Travel and Lodging | $6,457.07 |
| Education | $489.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $148,721.39 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $23,154.77 | 2020-2025 | Tremfya |
| Genzyme Corporation | $10,523.26 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $9,295.95 | 2023-2025 | Zoryve |
| Ucb, INC. | $2,441.05 | 2022-2025 | Bimzelx |
| Abbvie INC. | $1,249.61 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $599.71 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $475.09 | 2019-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $461.61 | 2019-2024 | |
| Dermavant Sciences, INC. | $401.74 | 2023 | Vtama |
| Celgene Corporation | $292.48 | 2019 | |
| Incyte Corporation | $250.05 | 2022-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $243.99 | 2023-2024 | Ilumya |
| Amgen INC. | $208.61 | 2020-2024 | Otezla |
| Galderma Laboratories, L.P. | $150.57 | 2021-2025 | Nemluvio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $140.28 | 2021-2024 | |
| Kyowa Kirin, INC. | $48.70 | 2022-2025 | Poteligeo |
| Regeneron Pharmaceuticals, INC. | $44.60 | 2023 | Dupixent |
| Janssen Scientific Affairs, LLC | $24.48 | 2023 | Tremfya |
| Fresenius Kabi USA, LLC | $21.06 | 2024 | Idacio |
| Genentech USA, INC. | $18.81 | 2022 | |
| Novo Nordisk INC | $18.18 | 2023 | Rybelsus, Ozempic |
| Organon LLC | $18.13 | 2025 | Vtama |
| Merz North America, INC. | $15.32 | 2019 | |
| Dermira, INC. | $15.27 | 2020 | |
| Mayne Pharma Commercial LLC | $14.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.65 | 2023 | Spevigo |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Biofrontera INC. | $12.56 | 2021 | |
| Nabriva Therapeutics, Plc | $11.91 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $11.24 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Ashack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.